Kornimate/medical-research-clean huggingface dataset:
evaluation of marginal bone loss and associated factors around ziacom dental implants with different prosthetic connection

Conditions: Jaw, Edentulous, Partially

Summary: dental implants may suffer from bone loss around them, particularly at the upper portion where the prosthesis starts. the connection between both parts of the tooth restoration is key for avoiding micromovement during chewing, bacterial contamination and initiation of bone loss. thus, investigating factors related to this bone loss in different types of implant-prosthetic connections is key for promoting better use of available therapeutics devices. in this study, we will study marginal bone levels over time as well as bacterial contamination and inflammatory markers in the peri-implant sulcus around implants with connical connection and compare them with those obtained when using implants with internal hexagonal connection. the hypothesis is that bone loss will be higher in implants with hexagonal connection associated with a pathological microbiome in the sulcus that induces a higher inflammatory response.


Eligibility criteria:
inclusion criteria: * one missing tooth in the premolar or molar area with both opposing and adjacent teeth (mesial and distal). exclusion criteria: * one-stage bone augmentation. * uncontrolled type 1 or 2 diabetes (hga1c\>8). * known auto-immune or inflammatory disease. * severe hematologic disorders, such as hemophilia or leukemia. * local or systemic infection that may compromise normal healing (e.g., extensive periapical pathology). * liver or kidney dysfunction/failure. * currently receiving cancer treatment or within 18 months from completion of radio- or chemotherapy. * long-term history of oral bisphosphonates use (i.e., 10 years or more). * history of intravenous bisphosphonates. * long-term (\>3 months) history of antibiotics or drugs known to alter the inflammation and/or immunological system 3 months before inclusion. * severe osseous diseases (e.g., paget disease of bone). * pregnant women or nursing mothers. * not able or not willing to follow instructions related to the study procedures.
amotivational syndrome and fatigue in neurosurgery

Conditions: Cerebral Injury; Motivation; Fatigue

Summary: depression is a major public concern associated with profound distress, intense suffering, and impairment in social, professional and familial functioning. among the numerous symptoms defining depression, fatigue and motivation are not only frequent but also highly associated with poor quality of life and resistance to conventional antidepressant. recent data, mainly obtained in animals, suggest that these symptoms may be linked to inflammatory processes within the central nervous system. yet access to the brain is too invasive for exploring this link in patients with psychiatric conditions. however, certain conditions in neurosurgery, such as aneurysm rupture, require external evacuation, over several days or weeks, of the fluid bathing the brain through a catheter directly inserted into it. critically, these patients also exhibit extreme exhaustion and fluctuating motivation, allowing to investigate the involvement of neuroinflammation in lack of motivation and fatigue by carrying out repeated motivation assessments with short behavioral tests (around ten minutes), while performing an analysis of inflammation markers in the fluid evacuated from the brain. the identification of inflammatory mechanisms underlying lack of motivation and fatigue could lead to the development of treatments for both resistant depression and motivation deficits that largely hamper rehabilitation in neurosurgery.


Eligibility criteria:
inclusion criteria: * age \>= 18 years old * patients required an external cerebrospinal fluid drainage exclusion criteria: * pregnant or breast feeding patient * patient under legal protection * patient opposition to participate in this study

Keywords: cerebrospinal fluid
hormone therapy effects on cvd risk factors

Conditions: Cardiovascular Diseases; Coronary Disease; Heart Diseases; Postmenopause

Summary: to conduct extended analysis of the postmenopausal estrogen/progestins intervention pepi trial database to address questions related to cardiovascular disease risk factor response and the possible determinants of this response.

background: cardiovascular disease is the leading cause of death among postmenopausal women. growing evidence exists that hormone replacement therapy (hrt) may reduce cardiovascular disease and mortality. this has led to the use of postmenopausal hrt for primary prevention of heart disease, however it remains unresolved which women are likely to benefit most from this clinical approach. this is a complicated question because many potential mechanisms are involved by which hormone therapy (hrt) may confer cardioprotection. the postmenopausal estrogen/progestins intervention (pepi) trial examined the relative impact of four regimens of hormone therapy on a range of cardiovascular disease risk factors (e.g. lipids, blood pressure, insulin/glucose, hemostasis factors). the trial was well conducted; its data have been thoroughly edited and have yielded a series of important publications. to date, however, publications have focused on average effects without a thorough exploration of the range of, and interplay among, the various effects across the 875 enrolled in the trial. design narrative: the study extended the analysis of pepi data by: 1) characterizing the distributions of responses to hormone therapy with respect to risk factors for cardiovascular disease (lipids/lipoproteins, blood pressure, insulin/glucose, hemostasis factors); 2) examining the multivariate patterns of treatment effects among these cardiovascular risk factors and on other outcomes (symptomatology, bone, endometrial); 3) examining clinical and demographic factors that may affect these relationships and, in doing so, characterizing women who may vary with respect to their "sensitivity" to the separate effects of estrogen and progestin therapy; 4) examining closely patterns of adherence and their relationship to response. an experienced team of statisticians/epidemiologists conducted and planned to publish results from these analyses. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
coq10 and prednisone in non-ambulatory dmd

Conditions: Duchenne Muscular Dystrophy

Summary: this study will help determine if coq10 and prednisone, alone and as a combination decrease the decline in cardiopulmonary and skeletal muscle function that occurs in the wheelchair confined phase of dmd. participants who are enrolled in this study should not have taken any corticosteroids within the last six months. this is a 13-month, prospective, randomized study comparing a daily prednisone arm (0.75mg/kg/day), a coq10 arm (serum of greater than 2.5 ug/ml) and a combination arm (prednisone and coq10) with an enhanced standard of care arm in wheelchair confined males age 10 to 18 years with an established dmd diagnosis.

duchenne muscular dystrophy (dmd) is the most common form of muscular dystrophy affecting 1:3500 male births worldwide. despite an increase in our understanding of the disorder since the discovery and characterization of the causative gene and its product dystrophin in 1987, current therapeutic management remains largely supportive. improvement in the treatment of dmd will depend upon the development of better therapies. affected boys become symptomatic at 3 to 5 years of age with proximal leg weakness that impairs mobility, ability to get up from a squat, and precludes a normal ability to run. by 8 years of age, some affected boys begin to lose the ability to walk and resort to a wheelchair for mobility. this shift from the ambulant to non-ambulant phase occurs in all boys with a diagnosis of dmd by age 12 years. in this study, participants will be randomized into groups after being screened to determine eligibility. participants will then be followed for a 12-month investigation period.

Eligibility criteria:
inclusion criteria: * age 10-18 years * non-ambulatory (primary mode of transportation is via wheelchair for 3 years or less) * confirmed dmd diagnosis * steroid-naive for the 6 months prior to screening * stable dose of b-blocker or ace inhibitor medication for the 6 months prior to screening, if taking either of these medications * ability to provide reproducible repeat qmt grip score within 15% of first assessment score * has not participated in other therapeutic research protocol within the last 6 months prior to screening * ability to swallow tablets exclusion criteria: * failure to achieve one or more of the diagnostic inclusion criteria cited above * symptomatic dmd carrier * use of carnitine, other amino acids, creatine, glutamine, coq10 or any herbal medicines (this would not include herbal teas unless they are consumed daily with intended medicinal effect) within the last 3 months * history of significant concomitant illness or significant impairment of renal or hepatic function, or other contraindication to steroid therapy * positive ppd * no prior exposure to chickenpox and no immunization against chicken pox * baseline serum coq10 level of 5.0mg/ml or greater

Keywords: muscular dystrophy duchenne coq10 prednisone
adequate dosage of sugammadex on thyroid surgery

Conditions: Thyroid Surgery

Summary: this study was designed to compare two dosage of sugammadex after tracheal intubation for optimal condition of continuous intraoperative neuromonitoring in thyroid surgery to protect recurrent laryngeal nerve.

vocal cord paralysis is not a rare complication in thyroid surgery. nerve monitoring technique has been developed, and many clinicians use the technique for saving the concerned nerves. many studies showed that the effect of sugammadex on reverse of neuromuscular blocking after tracheal intubation. however, optimal dosage was not founded for sugammadex. this randomized controlled trial is to compare 1 mg/kg and 2 mg/kg as dosage of sugammadex for optimal continuous intraoperative neuromonitoring in thyroid surgery to prevent vocal cord paralysis.

Eligibility criteria:
inclusion criteria: * the patients who need to open thyroid surgery exclusion criteria: * who doesn't agree to enroll * who has to receive other drug rather than rocuronium for muscle relaxant

Keywords: neuromonitoring thyroid surgery
bleeding rate after egd and colonoscopy in patients who continue to take antithrombotic agents

Conditions: Bleeding After GI Endoscopy

Summary: the bleeding rate of both egd (including biopsy) and colonoscopy (including biopsy, cold or hot snare polypectomy, or emr) in patients who continue to take various antithrombotic drugs is studied prospectively. the immediate or delayed bleeding that requires hemostatic clipping or other endoscopic treatments is defined as the bleeding. immediate bleeding requiring hemostatic clipping is defined as spurting or oozing which continued for more than 30 seconds. delayed bleeding is defined as bleeding that requires the endoscopic treatment within 2 weeks after endoscopy. prophylactic clipping is not performed after taking biopsy and doing polypectomy. additionally, investigators evaluate the rate of injured submucosal arteries of the excised specimen when the bleeding occurs.


Eligibility criteria:
inclusion criteria: * inclusion criteria is all patients who continue to take antithrombotic drugs and undergo egd or colonoscopy exclusion criteria: * patients who take prophylactic clipping after biopsy or polypectomy american society of anesthesiologists physical status of class iv or v
investigating the role and electrophysiological characteristics of the human claustrum based on seeg

Conditions: Refractory Epilepsy; Consciousness, Loss of

Summary: this single-center prospective study aims to investigate the electrophysiological characteristics and functions of the human claustrum by analyzing clinical, imaging, and electrophysiological data from 14\~65-year-old patients with drug-resistant epilepsy.

stereoelectroencephalography (seeg) is a method for recording electrical activity from deep brain structures using implanted depth electrodes to provide a three-dimensional view of neuronal activity. direct electrical stimulation (des) is a neurosurgical technique that involves delivering electrical impulses to specific brain regions through implanted electrodes to map critical functional areas and to study the connectivity of brain regions. this study aims to investigate the electrophysiological characteristics and functions of the human claustrum by analyzing clinical, imaging, and electrophysiological data from patients aged 14 to 65 implanted intracranial electrodes , with a specific focus on electrodes targeting the claustrum. this research forms part of a broader initiative to explore the functions of cortical and subcortical regions based on seeg.

Eligibility criteria:
inclusion criteria: 1. the patients were diagnosed with drug-resistant epilepsy. 2. the patients underwent stereoelectroencephalography (seeg) implantation for pre-surgical evaluation of epilepsy, with at least one electrode target reaching the claustrum 3. participants/parents/legal guardian provide informed consent for inclusion exclusion criteria: 1. subjects that experience surgical complications during the implant procedure will be excluded from the study

Keywords: refractory epilepsy consciousness claustrum
the efficacy of 10-day or 14-day course of bismuth-containing quadruple therapy:a randomized clinical trial

Conditions: Helicobacter Pylori Infection

Summary: the researchers collect treatment-naive h.pylori-positive patients from the outpatient clinic. the subjects were randomized to receive a 10-day or 14-day course of tegoprazan bismuth-containing quadruple eradication therapy at 6 weeks after treatment, subjects underwent another 13c-urea breath test. calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

the researchers collect treatment-naive h.pylori-positive patients from the outpatient clinic. if the subject meets the selection criteria but not the exclusion criteria, and signs an informed consent form, the researchers randomized the subjects in groups: subjects received a 10-day or 14-day course of tegoprazan bismuth-containing quadruple eradication therapy. the medication of groups are as follows. 6-8 weeks after the eradication treatment, the subjects will review the 13c-urea breath test, and the researcher records the results. after all subjects were tested, the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group were calculated. according to the course of treatment, it is randomized into a 10-day treatment group and a 14-day treatment group. the two groups of bismuth quadruple regimens are the same, as follows: amoxicillin 1000mg bid+ tetracycline 500mg qid+ bismuth + tegoprazan 50mg bid

Eligibility criteria:
inclusion criteria: * patients aged 18-70. * patients with h.pylori infection (positive for any of the following: 13c/14c-urea breath test, histopathology test, rapid urease test, stool h.pylori antigen test). * patients who have not previously received helicobacter pylori eradication therapy exclusion criteria: * patients with serious underlying diseases, such as liver insufficiency (aspartate aminotransferase or alanine aminotransferase greater than 1.5 times the normal value), renal insufficiency (cr≥2.0mg/dl or glomerular filtration rate \<50 ml/min), immunosuppression, malignant tumors, coronary heart disease or coronary artery stenosis ≥75%. * patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial. * patients with active gastrointestinal bleeding. * patients with a history of upper gastrointestinal surgery. * patients allergic to treatment drugs. * patients with medication history of bismuth agents, antibiotics, proton pump inhibitor and other drugs within 4 weeks * patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse * patients who are unwilling or incapable to provide informed consents.
timing of maternal antibiotic prophylaxis during a cesarean section and the early infant gut microbiome

Conditions: Microbial Colonization; Antibiotic Side Effect; Cesarean Section Complications

Summary: in this study, investigators seek to determine whether the timing of antibiotics given to mothers during an elective c-section affects the composition of their infant's gut microbiome. to do this, a randomized controlled trial (rct) was carried out with women undergoing elective c-sections. these women were either given antibiotics before the skin incision (ab+) or after the umbilical cord was clamped (ab-).

rationale: during a caesarean delivery, umbilical cord clamping can occur before or after administering a perioperative prophylactic antibiotic to the mother. if the cord is clamped before the antibiotic administration, this antibiotic cannot reach the infant. conversely, if the cord is clamped after the antibiotic administration, these maternal antibiotics cross the placenta and enter the infant's circulation. in this study, investigators hypothesize that such antibiotics modify the composition and functionality of the neonatal gut microbiome. a changed neonatal microbiome associates with the onset of asthma, allergies, type 1 diabetes, and obesity later in life. such a small intervention could influence the future health of the infant significantly. objective: the primary aim of this study is to contrast the composition and functionality of the neonatal gut microbiome from mothers given antibiotic prophylaxis before skin incision with the microbiome of neonates from mothers given the antibiotic after umbilical cord clamping during an elective caesarean delivery. study design: randomized controlled trial study population: pregnant women at \>38 weeks of gestation undergoing elective caesarean section at the umcg will be randomized into two groups. the gut microbiome of the neonates from both groups will be analyzed. intervention: the timing of umbilical cord clamping differs between the two groups. one gram of cefazolin (once, intravenous) will be administered to one group before skin incision, while 1g cefazolin will be given to another group after umbilical cord clamping during an elective caesarean section. main study parameters/endpoints: the primary endpoint of this study is the variance in the composition and functionality of the neonatal gut microbiome over a year, contrasting neonates from mothers given antibiotic prophylaxis before skin incision with neonates from mothers given the antibiotic after umbilical cord clamping.

Eligibility criteria:
inclusion criteria: * females undergoing elective cs at the umcg * gestational age in weeks equal to or above 38 weeks exclusion criteria: * cephalosporin allergy * exposure to antibiotic agent 2 weeks before cs * temperature \>37.5 c before cs * pre-labour rupture of membranes * emergency cs * no -20 freezer at home * no command of the dutch language
effects of different peep levels on work of breathing in morbidly obese patients prior to and after extubation

Conditions: Obesity

Summary: the main purpose of this study is to define at the bedside the "titrated-peep" level for obese patients that increases the likelihood of extubation and ventilator liberation. the investigators hypothesized that a titrated level of peep ("titrated-peep") during sbt will keep the lung recruited, maintain oxygenation, and decrease the work of breathing resulting in successful ventilator liberation. in addition, post-extubation the investigators hypothesize that these patients will require noninvasive ventilatory support in the form of cpap at the level of "titrated-peep" used during the sbt.

the high wob of morbidly obese patients is associated with respiratory muscle fatigue and failure in extubation. the investigators hypothesized that the use of a titrated peep level prior to and after extubation might improve successful extubation rates and avoid re-intubation. in this study, patients will be awake and ventilated in the pressure support ventilation (psv) mode. the investigators will apply different peep levels to measure wob, transpulmonary pressure and characterize the response of the respiratory system to increasing or decreasing peep. the "titrated-peep" will be identified as the peep level associated with the lowest value of respiratory system elastance and an end expiratory transpulmonary pressure of 2 cmh2o. then the participants will have two spontaneous breathing trials; one at peep 0-5 cmh2o, and the other at the "titrated-peep" level, with psv=0 and fio2 unchanged. after extubation, the participants will first receive cpap set at "titrated-peep", then spontaneous breathing. electrical impedance tomography (eit), respiratory system mechanics and gas exchange will be recorded during the study. the investigators believe that the real-time determination of "titrated-peep" can guide the treatment of mechanical ventilation and give us a better understanding of the physiology and pathophysiology of morbidly obese patients. as a result, this study will improve patient safety; reduce the duration of mechanical ventilation, complications and healthcare costs.

Eligibility criteria:
inclusion criteria: * intubated and mechanically ventilated; * weaning from mechanical ventilation; * bmi ≥ 35 kg/m2 with waist circumference \> 88 cm for women; waist circumference \> 102 cm for men. * a well functioning arterial line. exclusion criteria: * known presence of esophageal varices * recent esophageal trauma or surgery * severe thrombocytopenia (ptl ≤ 5,000/mm3) * severe coagulopathy (inr ≥ 4) * presence of pneumothorax * pregnancy * pacemaker and/or internal cardiac defibrillator

Keywords: mechanical ventilation positive end-expiratory pressure work of breathing morbidly obese